Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)
SOUTH SAN FRANCISCO, July 02, 2007 /PRNewswire/ -- Portola
Pharmaceuticals, Inc. announced today that it will present clinical
and preclinical data on its oral Factor Xa inhibitor and on its
intravenous and oral ADP receptor antagonist at the
XXI Congress of
the International Society of Thrombosis...
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
SAN FRANCISCO, July 10, 2007 /PRNewswire/ -- Portola
Pharmaceuticals, Inc. announced positive Phase II data on its lead
compound, PRT054021, an oral Factor Xa inhibitor, today at the XXI
Congress of the International Society on Thrombosis and Haemostasis
(ISTH) in Geneva, Switzerland. The EXPERT t...
Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
HORSHAM, Pa.--(BUSINESS WIRE)--Jul 11, 2007 - Neose Technologies,
Inc. (Nasdaq GM:NTEC) today announced that two poster presentations
were presented with its collaborative partner, Novo Nordisk A/S,
relating to GlycoPEGylated recombinant Factor VIIa at the XXIst
Congress of the International Societ...
Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
...pathologies: A single center experience International Society of Endovascular Specialists International Congress
xxi Endovascular Interventions
...
Portola Pharmaceuticals Announces Positive Phase II Results for
PRT054021 for Prevention of Venous Thromboembolism Following Total
Knee Replacement Surgery
... Data to be Presented at the
xxi Congress of the International
Society on Thrombosis and Haemostasis
SOUTH ...und into further clinical trials. Data
from EXPERT will be presented at the
xxi Congress of the
International Society on Thrombosis and Haemostasis in Gene...
Othera Pharmaceuticals Announces Upcoming Presentation Based Upon
Expanded Understanding of Lead Compound Mechanism of Action
...ell as studies on novel,
orally-available analog compounds under development for
non-ophthalmic indications. Dr. Mousa's talk will be presented at
the
xxi International Society on Thrombosis and Haemostasis (ISTH)
Congress in Geneva, Switzerland on July 9, 2007. The ISTH holds its
congress every other ye...
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery
... GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase III
clinical trial data presented today at the
xxi International
Society on Thrombosis and Haemostasis (ISTH) Congress demonstrate
that once-daily rivaroxaban achieved superior efficacy in the
preventi...
Phase III Trial Results Show Superiority of Rivaroxaban over
Enoxaparin for the Prevention of Venous Thromboembolism in Patients
Undergoing Knee Replacement Surgery
...Compared with Enoxaparin with Similarly Low Bleeding
Rates
GENEVA, July 8, 2007 - Late-breaking Phase III clinical trial
data presented today at the
xxi International Society on Thrombosis
and Haemostasis (ISTH) Congress demonstrate that once-daily
rivaroxaban (Xarelto®) achieved superior efficacy ...
IRB Barcelona to coordinate two European projects on biomedicine
...r professor at the University of Barcelona, will coordinate a pioneering project to fight against diabetes, a disease described as the epidemic of the
xxi century. The MITIN Project is innovative because it will be the first time that bioinformatics is applied to obtain information about complex diseases...
CO2 increase in the atmosphere augments tolerance of barley to salinity
...ction in its growth.
The Intergovernmental Panel on Climate Change (IPCC) predicts that the CO 2 concentration in the atmosphere at the end of the
xxi century will double current levels. An increase contributed to by human activity through the combustion of fossil fuels and the destruction of forests...